Profile data is unavailable for this security.
About the company
Firebrick Pharma Limited is an Australia-based pharmaceutical company. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The Company has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.
- Revenue in AUD (TTM)293.42k
- Net income in AUD-2.63m
- Incorporated2012
- Employees--
- LocationFirebrick Pharma LtdLevel 10, 440 Collins StreetMELBOURNE 3000AustraliaAUS
- Phone+61 30030-1874
- Websitehttps://firebrickpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrux Ltd | 4.53m | -5.95m | 6.16m | 43.00 | -- | 5.98 | -- | 1.36 | -0.0176 | -0.0176 | 0.0129 | 0.0025 | 0.5594 | -- | 1.36 | -- | -73.45 | -48.30 | -148.89 | -61.75 | 100.00 | -- | -131.29 | -101.52 | -- | -18.59 | 0.7804 | -- | -44.08 | 3.32 | -2.50 | -- | -54.56 | -- |
| Nutritional Growth Solutions Ltd | 3.03m | -4.03m | 7.33m | -- | -- | -- | -- | 2.42 | -0.0437 | -0.0437 | 0.0325 | -0.0119 | 3.26 | 4.05 | 33.35 | -- | -433.20 | -130.49 | -- | -187.56 | 26.70 | 40.32 | -132.89 | -143.99 | 0.1206 | -19.99 | -- | -- | -16.86 | 15.95 | -0.2074 | -- | -- | -- |
| Zelira Therapeutics Ltd | 660.00 | -3.63m | 7.38m | 8.00 | -- | -- | -- | 11,176.12 | -0.3172 | -0.3172 | 0.00006 | -0.3749 | 0.0002 | 0.0102 | 0.003 | -- | -118.74 | -50.35 | -- | -56.97 | -1,236.36 | 43.05 | -583,283.30 | -2,379.12 | 0.0244 | -6.50 | -- | -- | -99.30 | -77.07 | 90.08 | -- | -- | -- |
| Immuron Ltd | 7.29m | -5.22m | 9.80m | 7.00 | -- | 0.8698 | -- | 1.34 | -0.0226 | -0.0226 | 0.0316 | 0.0345 | 0.5675 | 1.50 | 4.40 | 1,041,000.00 | -40.62 | -27.84 | -49.64 | -30.60 | 65.39 | 70.18 | -71.58 | -182.34 | 4.19 | -- | 0.00 | -- | 48.63 | 23.67 | 24.81 | -- | -- | -- |
| Tissue Repair Ltd | 3.02m | -4.24m | 11.19m | -- | -- | 0.8041 | -- | 3.71 | -0.0701 | -0.0701 | 0.0499 | 0.2301 | 0.1777 | -- | 60.84 | -- | -24.96 | -24.25 | -26.50 | -25.27 | -- | -- | -140.49 | -518.54 | 22.40 | -- | 0.00 | -- | 236.85 | -- | -2.43 | -- | -- | -- |
| Epsilon Healthcare Ltd | 6.13m | -6.12m | 12.13m | -- | -- | -- | -- | 1.98 | -0.0164 | -0.0164 | 0.0167 | -0.0097 | 0.462 | -- | 4.95 | -- | -46.14 | -33.37 | -156.14 | -46.46 | 52.23 | 49.34 | -99.85 | -136.16 | 0.3775 | -3.92 | 1.67 | -- | -15.81 | 3.16 | -403.56 | -- | -32.83 | -- |
| Calmer Co International Ltd | 8.03m | -3.99m | 13.76m | -- | -- | 7.12 | -- | 1.71 | -0.0015 | -0.0015 | 0.0029 | 0.0006 | 1.60 | 3.29 | 14.33 | -- | -79.73 | -109.82 | -171.17 | -197.50 | 42.49 | 41.18 | -49.69 | -128.71 | 1.22 | -11.32 | 0.5482 | -- | 88.48 | 59.99 | -7.13 | -- | 27.67 | -- |
| Oncosil Medical Ltd | 1.26m | -15.10m | 14.85m | 2.00 | -- | 3.13 | -- | 11.77 | -1.37 | -1.37 | 0.1148 | 0.217 | 0.182 | -- | 2.18 | -- | -217.79 | -97.54 | -382.54 | -117.83 | -78.62 | -54.05 | -1,196.80 | -1,258.41 | -- | -146.89 | 0.022 | -- | 116.34 | -15.15 | -26.74 | -- | -6.31 | -- |
| Firebrick Pharma Ltd | 293.42k | -2.63m | 17.11m | -- | -- | 9.81 | -- | 58.30 | -0.0126 | -0.0126 | 0.0014 | 0.0069 | 0.1386 | 0.8696 | 0.4855 | -- | -124.44 | -98.41 | -143.50 | -109.28 | 35.72 | -- | -897.84 | -5,384.55 | 4.75 | -- | 0.00 | -- | 1,920.80 | -- | -124.04 | -- | -- | -- |
| TrivarX Ltd | 1.13m | -943.23k | 24.23m | 4.00 | -- | 1.03 | -- | 21.39 | -0.0018 | -0.0018 | 0.0023 | 0.0204 | 0.0923 | -- | -- | -- | -7.68 | -33.47 | -8.32 | -37.46 | -- | -- | -83.27 | -373.85 | -- | -27.05 | 0.0132 | -- | 26.38 | 3.89 | 34.25 | -- | 6.29 | -- |
